NCT01398501View on ClinicalTrials.gov

Sorafenib Maintenance Therapy for Patients With AML After Allogeneic Stem Cell Transplant

PHASE1CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

August 31, 2011

Primary Completion Date

September 30, 2015

Study Completion Date

August 31, 2016

Conditions
Acute Myeloid Leukemia
Interventions
DRUG

Sorafenib

Oral, 200 to 400 mg QD or BID

Trial Locations (2)

02114

Massachusetts General Hospital, Boston

02214

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

Dana-Farber Cancer Institute

OTHER

lead

Massachusetts General Hospital

OTHER

NCT01398501 - Sorafenib Maintenance Therapy for Patients With AML After Allogeneic Stem Cell Transplant | Biotech Hunter | Biotech Hunter